SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
It has been revealed that the maker of a powerful, addictive opioid drug is bankrolling the opposition to the effort to legalize and regulate marijuana for recreational use in Arizona.
The Phoenix New Times reported Thursday that Insys Therapeutics, the company behind the fentanyl-based medication Subsys, made a $500,000 donation to the group Arizonans for Responsible Drug Policy (ARDP), which is leading the campaign against Proposition 205.
On the ballot in November, Prop. 205 would allow people 21 years of age or older to possess up to one ounce of marijuana and grow up to six plants in their homes as well as establish a department to regulate the drug's cultivation and sale.
It appears that Insys is trying to "eliminate the competition," according to the New Times, which noted that the company "expects to soon launch a pharmaceutical version of THC, the main psychoactive ingredient in cannabis."
What's more, Insys is currently facing numerous state investigations for deceptively marketing and selling Subsys, which is intended to treat cancer pain, and coercing doctors to promote it to patients for off-label uses. Fentanyl is estimated to be 80 times as potent as morphine and hundreds of times more potent than heroin, according to the Centers for Disease Control and Prevention, and may be fatal to users.
"It's hard to imagine a more sinister donor than Insys Therapeutics Inc. in the eyes of pot legalization proponents, who long have claimed drug companies want to keep cannabis illegal to corner the market for drugs, some addictive and dangerous, that relieve pain and other symptoms," U.S. News & World Report wrote Thursday, summarizing the dynamic.
Responding to the news, J.P. Holyoak, chair of the Prop. 205 proponent group Campaign to Regulate Marijuana Like Alcohol, issued a press statement slamming the opposition to keeping the donation from "one of the more unscrupulous members of Big Pharma."
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance," Holyoak said.
He also pointed out their development of synthetic 'pharmaceutical cannabinoids,' and said, "It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets."
"Our opponents have made a conscious decision to associate with this company. They are now funding their campaign with profits from the sale of opioids -- and maybe even the improper sale of opioids," Holyoak continued. "Any time an ad airs against Prop. 205, the voters should know that it was paid for by highly suspect Big Pharma actors."
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
It has been revealed that the maker of a powerful, addictive opioid drug is bankrolling the opposition to the effort to legalize and regulate marijuana for recreational use in Arizona.
The Phoenix New Times reported Thursday that Insys Therapeutics, the company behind the fentanyl-based medication Subsys, made a $500,000 donation to the group Arizonans for Responsible Drug Policy (ARDP), which is leading the campaign against Proposition 205.
On the ballot in November, Prop. 205 would allow people 21 years of age or older to possess up to one ounce of marijuana and grow up to six plants in their homes as well as establish a department to regulate the drug's cultivation and sale.
It appears that Insys is trying to "eliminate the competition," according to the New Times, which noted that the company "expects to soon launch a pharmaceutical version of THC, the main psychoactive ingredient in cannabis."
What's more, Insys is currently facing numerous state investigations for deceptively marketing and selling Subsys, which is intended to treat cancer pain, and coercing doctors to promote it to patients for off-label uses. Fentanyl is estimated to be 80 times as potent as morphine and hundreds of times more potent than heroin, according to the Centers for Disease Control and Prevention, and may be fatal to users.
"It's hard to imagine a more sinister donor than Insys Therapeutics Inc. in the eyes of pot legalization proponents, who long have claimed drug companies want to keep cannabis illegal to corner the market for drugs, some addictive and dangerous, that relieve pain and other symptoms," U.S. News & World Report wrote Thursday, summarizing the dynamic.
Responding to the news, J.P. Holyoak, chair of the Prop. 205 proponent group Campaign to Regulate Marijuana Like Alcohol, issued a press statement slamming the opposition to keeping the donation from "one of the more unscrupulous members of Big Pharma."
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance," Holyoak said.
He also pointed out their development of synthetic 'pharmaceutical cannabinoids,' and said, "It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets."
"Our opponents have made a conscious decision to associate with this company. They are now funding their campaign with profits from the sale of opioids -- and maybe even the improper sale of opioids," Holyoak continued. "Any time an ad airs against Prop. 205, the voters should know that it was paid for by highly suspect Big Pharma actors."
It has been revealed that the maker of a powerful, addictive opioid drug is bankrolling the opposition to the effort to legalize and regulate marijuana for recreational use in Arizona.
The Phoenix New Times reported Thursday that Insys Therapeutics, the company behind the fentanyl-based medication Subsys, made a $500,000 donation to the group Arizonans for Responsible Drug Policy (ARDP), which is leading the campaign against Proposition 205.
On the ballot in November, Prop. 205 would allow people 21 years of age or older to possess up to one ounce of marijuana and grow up to six plants in their homes as well as establish a department to regulate the drug's cultivation and sale.
It appears that Insys is trying to "eliminate the competition," according to the New Times, which noted that the company "expects to soon launch a pharmaceutical version of THC, the main psychoactive ingredient in cannabis."
What's more, Insys is currently facing numerous state investigations for deceptively marketing and selling Subsys, which is intended to treat cancer pain, and coercing doctors to promote it to patients for off-label uses. Fentanyl is estimated to be 80 times as potent as morphine and hundreds of times more potent than heroin, according to the Centers for Disease Control and Prevention, and may be fatal to users.
"It's hard to imagine a more sinister donor than Insys Therapeutics Inc. in the eyes of pot legalization proponents, who long have claimed drug companies want to keep cannabis illegal to corner the market for drugs, some addictive and dangerous, that relieve pain and other symptoms," U.S. News & World Report wrote Thursday, summarizing the dynamic.
Responding to the news, J.P. Holyoak, chair of the Prop. 205 proponent group Campaign to Regulate Marijuana Like Alcohol, issued a press statement slamming the opposition to keeping the donation from "one of the more unscrupulous members of Big Pharma."
"You have a company using profits from the sale of what has been called 'the most potent and dangerous opioid on the market' to prevent adults from using a far less harmful substance," Holyoak said.
He also pointed out their development of synthetic 'pharmaceutical cannabinoids,' and said, "It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets."
"Our opponents have made a conscious decision to associate with this company. They are now funding their campaign with profits from the sale of opioids -- and maybe even the improper sale of opioids," Holyoak continued. "Any time an ad airs against Prop. 205, the voters should know that it was paid for by highly suspect Big Pharma actors."